Bringing the fundamentals into focus…
Back to BridgeBio Oncology Therapeutics, Inc.
How BridgeBio Oncology Therapeutics, Inc. stacks up
BBOT · against 208 other Healthcare companies of similar size
Valuation
33/ 100
Below the middle of the pack.
Ranked #101 of 209 · scores higher than 40% of peers
Bars: peers in each 10-point band of the valuation score40 peers with a valuation score of 30–39, including BBOT · Click a bar to see the companies
Why valuation scores 33?
Weighted metrics compared with all Healthcare companies.Mainly because of its earnings yield and free cash flow yield, which are weaker than most Healthcare peers.
- Cash exceeds market value plus debt, so EBITDA yield is not meaningful and is left out.
- Negative (a loss or cash outflow), so it counts as zero whatever the share price. Earnings yield: -97.9% vs peer median 1.5%
- Negative (a loss or cash outflow), so it counts as zero whatever the share price. Free cash flow yield: -81.5% vs peer median 0.0%
Metric by metric
Position: dot = BBOT, ranked from the worst peer (left) to the best (right); tick = middle, shaded = middle half of peers.| Metric | BBOT | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 193 reported | -97.8% | -4.1% | 7% | 30% | |
| EBITDA yieldHigher is better · 216 reported | -4604.6% | 1.4% | 2% | 50% | |
| Free cash flow yieldHigher is better · 130 reported | -81.5% | -12.3% | 5% | 20% | |
| Book yieldHigher is better · 199 reported | 173.8% | 61.8% | 92% | Context only |
Ranking by valuation score
Top 5 and the companies ranked around BBOT| Rank | Company | Market cap | Valuation | Overall |
|---|---|---|---|---|
| 1 | 1.1B HKD (≈$146M) | 99 | 72 | |
| 1 | 834M HKD (≈$107M) | 99 | 57 | |
| 1 | 1.4B HKD (≈$181M) | 99 | 61 | |
| 1 | 2.9B HKD (≈$365M) | 99 | 84 | |
| 1 | 29.0B JPY (≈$197M) | 99 | 56 | |
| 100 | 1.6B CNY (≈$223M) | 36 | 46 | |
| 101 | 40.1B JPY (≈$273M) | 33 | 45 | |
| 101 | 205M USD | 33 | 36 | |
| 101 | 111M USD | 33 | ||
| 101 | 186M USD | 33 | 43 | |
| 101 | 257M USD | 33 | 55 | |
| 101 | 274M USD | 33 | 57 | |
| 101 | 100M USD | 33 | 37 | |
| 101 | 110M USD | 33 | 38 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score